摘要
急性冠脉综合征是冠脉斑块破裂后激发的一个由中性粒细胞介导的与血栓形成有关的急性炎症过程 ,在细胞黏附分子、肿瘤坏死因子、巨细胞移动抑制因子、金属蛋白酶、核转录因子 -κB等多种炎性因子中 ,C反应蛋白水平的升高不但与急性冠脉事件高度相关 ,还与疗效及预后相关 ;他汀类调脂药对冠心病患者的保护远超出其血脂下降本身 ,他汀类抗炎机制可能与降脂作用无关 ,新近研究发现大剂量他汀类如阿托伐他汀 ( 80 mg·d- 1有快速炎症抑制作用和消退斑块作用 ,其炎症抑制效价与剂量相关 。
OBJECTIVE Acute coronary artery syndrome(ACS) is a serial acute imflammatory process,which is associated with thrombogenesis conducted by neutrophilic granulocyte.Many cellular factors involved in the process including cellular adhesion molecule(CAM),tumor necrosis factor macrophage migration inhibition factor,metalloprotease nuclear transcription factor-κB,Especially C-reactive protein,it's elavation associated with ACS events and prognosis.More and more evidences support that,the protection of Statins on coronary artery disease are beyond the decline of lipid itself,the anti-imflammatory effect of Statins on coronary atherosclerotic lesion is independence with the lowering of blood lipid;New studies showed that large dose such as atorvastatin 80mg·d -1can rapidly anti-imflammation and diminution coronary atherosclerotic score.
出处
《海峡药学》
2004年第6期5-7,共3页
Strait Pharmaceutical Journal
关键词
惠性冠脉综合征
炎症因子
他汀类调脂药
Acute coronary artery syndrome(ACS)
Inflammatory factor
Statins
